Л. В. Мороз

738 total citations · 1 hit paper
26 papers, 550 citations indexed

About

Л. В. Мороз is a scholar working on Epidemiology, Hepatology and Molecular Biology. According to data from OpenAlex, Л. В. Мороз has authored 26 papers receiving a total of 550 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Epidemiology, 10 papers in Hepatology and 6 papers in Molecular Biology. Recurrent topics in Л. В. Мороз's work include Hepatitis C virus research (9 papers), Liver Disease Diagnosis and Treatment (6 papers) and Hepatitis B Virus Studies (5 papers). Л. В. Мороз is often cited by papers focused on Hepatitis C virus research (9 papers), Liver Disease Diagnosis and Treatment (6 papers) and Hepatitis B Virus Studies (5 papers). Л. В. Мороз collaborates with scholars based in Ukraine, United States and United Kingdom. Л. В. Мороз's co-authors include Oliver Lenz, Antonio Craxı̀, Ronald Kalmeijer, Michael Fried, Sivi Ouwerkerk‐Mahadevan, Maria Beumont‐Mauviel, Ira M. Jacobson, Graham R. Foster, Gregory J. Dore and Rekha Sinha and has published in prestigious journals such as The Lancet, Journal of Clinical Investigation and SHILAP Revista de lepidopterología.

In The Last Decade

Л. В. Мороз

21 papers receiving 515 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

2014 333 citations Ira M. Jacobson, Gregory J. Dore et al. The Lancet profile →

Peers

Countries citing papers authored by Л. В. Мороз

Since Specialization

Citations

This map shows the geographic impact of Л. В. Мороз's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Л. В. Мороз with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Л. В. Мороз more than expected).

Fields of papers citing papers by Л. В. Мороз

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Л. В. Мороз. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Л. В. Мороз. The network helps show where Л. В. Мороз may publish in the future.

Co-authorship network of co-authors of Л. В. Мороз

This figure shows the co-authorship network connecting the top 25 collaborators of Л. В. Мороз. A scholar is included among the top collaborators of Л. В. Мороз based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Л. В. Мороз. Л. В. Мороз is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genotype Distribution and Characteristics of Chronic Hepatitis C Infection in Estonia, Latvia, Lithuania, and Ukraine: The RESPOND-C Study 2023 ·Medicina ·Ligita Jančorienė, Baiba Rozentāle, Ieva Tolmane, Agita Jēruma, (unknown), (unknown), Jonas Valantinas, Limas Kupčinskas, (unknown), (unknown), Arvydas Ambrozaitis, (unknown), Л. В. Мороз, Robert Flisiak, (unknown)	0
2	Quercetin effectiveness in patients with COVID-19 associated pneumonia 2021 ·SHILAP Revista de lepidopterología ·И. А. Зупанец, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Л. В. Мороз, (unknown), (unknown), Roman Fishchuk, (unknown), (unknown), (unknown)	6
3	Colloidal Silicon Dioxide in Tablet form (Carbowhite) Efficacy in Patients with Acute Diarrhea: Results of Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study 2020 ·Scientific Reports ·(unknown), Л. В. Мороз, (unknown), (unknown), (unknown), (unknown)	21
4	MODERN APPROACHES IN MANAGEMENT OF CHILDREN WITH CHRONIC HEPATITIS B IN REMISSION OF ACUTE LYMPHOBLASTIC LEUKEMIA. 2020 ·PubMed ·(unknown), Л. В. Мороз, (unknown), Omkar Singh	2
5	Peculiarities of Immune Status among Young Patients with Community-Acquired Pneumonia (CAP) during Cytomegaloviral Persistence (CMVP) 2017 ·(unknown), (unknown), Л. В. Мороз	1
6	Клинический случай тяжелого течения микст-малярии (Рl. falciparum, Рl. malariae) у пациента украинского происхождения 2017 ·SHILAP Revista de lepidopterología ·(unknown), Л. В. Мороз, (unknown), (unknown), (unknown)	1
7	IFNL4 polymorphism as a predictor of chronic hepatitis C treatment efficiency in Ukrainian patients 2016 ·Cytology and Genetics ·(unknown), (unknown), (unknown), (unknown), (unknown), Л. В. Мороз, Л. А. Лившиц	2
8	VITAMIN D AS ONE OF PREDICATORS OF THE STABLE VIRAL RESPONSE TO ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIS HEPATITIS С 2016 ·Л. В. Мороз, (unknown), (unknown), (unknown)	0
9	ITPA gene variant may protect against anemia induced during pegylated interferon Alfa and Ribavirin combination treatment in Ukrainian patients with chronic hepatitis C 2015 ·Cytology and Genetics ·(unknown), (unknown), (unknown), Л. В. Мороз, Л. А. Лившиц	1
10	Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial breakdown → 2014 ·The Lancet ·Ira M. Jacobson, Gregory J. Dore, Graham R. Foster, Michael Fried, Monica Radu, V. V. Rafalsky, Л. В. Мороз, Antonio Craxı̀, Monika Peeters, Oliver Lenz, Sivi Ouwerkerk‐Mahadevan, Guy De La Rosa, Ronald Kalmeijer, Jane Scott, Rekha Sinha, Maria Beumont‐Mauviel	333
11	1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL 2013 ·Journal of Hepatology ·Ira M. Jacobson, G.J. Dore, Graham R. Foster, Michael Fried, (unknown), Vladimir Rafalskiy, Л. В. Мороз, Antonio Craxı̀, Marc Peeters, Oliver Lenz, Sivi Ouwerkerk‐Mahadevan, Ronald Kalmeijer, Maria Beumont‐Mauviel	71
12	Controlled release recombinant human interferon‐α_2b for treating patients with chronic hepatitis C genotype 1: a phase 2a clinical trial 2010 ·Journal of Viral Hepatitis ·(unknown), (unknown), Л. В. Мороз, (unknown), (unknown), (unknown), Arno Kromminga, Mahlon M. Wilkes, Ewoud J. van Hoogdalem, John Eric Humphries	5
13	HIV and hepatitis C virus infections among hanka injection drug users in central Ukraine: a cross-sectional survey 2009 ·Harm Reduction Journal ·Kostyantyn Dumchev, (unknown), Han‐Zhu Qian, (unknown), (unknown), (unknown), Л. В. Мороз, Joseph E. Schumacher	33
14	848 VIRAL KINETICS DURING TREATMENT WITH A CONTROLLED-RELEASE RECOMBINANT INTERFERON ALFA 2B IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS 2008 ·Journal of Hepatology ·Eva Herrmann, Stefan Zeuzem, (unknown), Л. В. Мороз, (unknown), (unknown), Ewoud J. van Hoogdalem, John Eric Humphries	2
15	A situational picture of HIV/AIDS and injection drug use in Vinnitsya, Ukraine 2005 ·Harm Reduction Journal ·(unknown), Joseph E. Schumacher, Kostyantyn Dumchev, Л. В. Мороз	21
16	Use of glutathione inhibitors and glutathione transferases to overcome tumor resistance to cytostaticsin vivo 1995 ·Bulletin of Experimental Biology and Medicine ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Л. В. Мороз	1
17	Resistance to Doxorubicin in Tumor Cells in vitro and in vivo after Pretreatment with Verapamil 1991 ·Chemotherapy ·(unknown), Thomas Efferth, J Mattern, Л. В. Мороз, M Volm	9
18	Effect of Triton X-100 on accumulation and therapeutic action of doxorubicin in mice with leukemia P-388 and with induced resistance to the cytostatic 1991 ·Bulletin of Experimental Biology and Medicine ·(unknown), (unknown), (unknown), Л. В. Мороз	1
19	[Therapeutic use of carminomycin in soft tissue sarcomas]. 1976 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Н И Переводчикова, (unknown), Mikhail Lichinitser, Л. В. Мороз	2
20	The Polymorphic Forms of α1-Acid Glycoprotein of Normal Caucasian Individuals* 1964 ·Journal of Clinical Investigation ·Karl Schmid, J. Paul Binette, (unknown), Л. В. Мороз, (unknown)	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact